Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-2-21
|
| pubmed:abstractText |
Peptides are of potential interest in the field of gene therapy but require modification by genetic engineering to facilitate their secretion. Amino terminal addition of a signal peptide is not always sufficient to achieve this goal, as found in this study for beta-endorphin. To overcome this problem, addition of the pre-pro-sequence of mouse nerve growth factor to beta-endorphin was tested. Retrovirus-mediated expression of a hybrid construct of the pre-pro-sequence of nerve growth factor and human beta-endorphin in primary fibroblasts resulted in the secretion of beta-endorphin immunoreactivity at a rate of 620 pg/h/10(6) cells. Analysis of the secreted beta-endorphin immunoreactivity with reverse-phase HPLC, immunoassays using three different antibodies, and an assay for the specific displacement of [3H][D-Ala2,N-MePhe4,Gly-ol5]enkephalin from mu-opioid receptors suggests that the pre-pro-sequence is cleaved off from the pre-pro-sequence/beta-endorphin construct prior to secretion, resulting in bona fide beta-endorphin. Transplantation of beta-endorphin-secreting cells into brain or spinal cord may provide a gene therapy approach for the treatment of chronic, opioid-sensitive pain states.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0022-3042
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
475-81
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7830038-3T3 Cells,
pubmed-meshheading:7830038-Animals,
pubmed-meshheading:7830038-Base Sequence,
pubmed-meshheading:7830038-Blotting, Northern,
pubmed-meshheading:7830038-Cell Line,
pubmed-meshheading:7830038-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:7830038-Fibroblasts,
pubmed-meshheading:7830038-Genetic Vectors,
pubmed-meshheading:7830038-Humans,
pubmed-meshheading:7830038-Mice,
pubmed-meshheading:7830038-Molecular Probes,
pubmed-meshheading:7830038-Molecular Sequence Data,
pubmed-meshheading:7830038-Nerve Growth Factors,
pubmed-meshheading:7830038-Protein Precursors,
pubmed-meshheading:7830038-Radioimmunoassay,
pubmed-meshheading:7830038-Rats,
pubmed-meshheading:7830038-Retroviridae,
pubmed-meshheading:7830038-Retroviridae Infections,
pubmed-meshheading:7830038-beta-Endorphin
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts.
|
| pubmed:affiliation |
Department of Neurosciences, University of California, San Diego, La Jolla 92093-0818.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|